Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 8, 2008, Pages 703-713

  Bjerner, Johan ^a   Høgetveit, Anita ^a   Wold Akselberg, Katrine ^a   Vangsnes, Kirsti ^a   Paus, Elisabeth ^a   Bjøro, Trine ^a   Børmer, Ole Petter ^a   Nustad, Kjell ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Age; Alfa foeto protein (AFP); CA125; CA19.9; Carcinoembryonic antigen (CEA); Confidence intervals; Fractional polynomials; Maximum likelihood; MUC1 (CA15.3); Neuron specific enolase (NSE); Reference intervals; Sex; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; NEURON SPECIFIC ENOLASE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; IMMUNORADIOMETRIC ASSAY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REFERENCE VALUE; REGRESSION ANALYSIS; SERUM; SMOKING;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCIN-1; PHOSPHOPYRUVATE HYDRATASE; REFERENCE VALUES; REGRESSION ANALYSIS; SCANDINAVIA;

EID: 54249096211     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510802126836     Document Type: Article

References (40)

1. Rustad P, Felding P, Franzson L, Kairisto V, Lahti A, Martensson A, et al. The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties. Scand J Clin Lab Invest 2004;64:271-84.
2. Rustad P, Simonsson P, Felding P, Pedersen M. Nordic Reference Interval Project Bio-bank and Database (NOBIDA): a source for future estimation and retrospective evaluation of reference intervals. Scand J Clin Lab Invest 2004;64:431-8.
3. PetitClerc C, Solberg HE. International Federation of Clinical Chemistry (IFCC). Expert Panel on theory of reference values. Approved recommendation (1987) on the theory of reference values. Part 2. Selection of individuals for the production of reference values. J Clin Chem Clin Biochem 1987;25:639-44.
4. Solberg HE, PetitClerc C. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values. Approved recommendation (1988) on the theory of reference values. Part 3. Preparation of individuals and collection of specimens for the production of reference values. J Clin Chem Clin Biochem 1988;26:593-8.
5. Solberg HE, Stamm D. International Federation of Clinical Chemistry, Scientific Division: approved recommendation on the theory of reference values. Part 4. Control of analytical variation in the production, transfer and application of reference values. Eur J Clin Chem Clin Biochem 1991;29:531-5.
6. Solberg HE. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of reference values. Part 1. The concept of reference values. J Clin Chem Clin Biochem 1987;25:337-42.
7. Solberg HE. International Federation of Clinical Chemistry (IFCC) and International Committee for Standardization in Haematology (ICSH). Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987;25:645-56.
8. Dybkaer R, Solberg HE. International Federation of Clinical Chemistry (IFCC) and International Committee for Standardization in Haematology (ICSH). Approved recommendation (1987) on the theory of reference values. Part 6. Presentation of observed values related to reference values. J Clin Chem Clin Biochem 1987;25:657-62.
9. Rustad P, Felding P, Lahti A. Proposal for guidelines to establish common biological reference intervals in large geographical areas for biochemical quantities measured frequently in serum and plasma. Clin Chem Lab Med 2004;42:783-91.
10. Bjerner J. Age-dependent biochemical quantities: an approach for calculating reference intervals. Scand J Clin Lab Invest 2007;67:707-22.
11. Pedersen MM, Rustad P, Simonsson P. Certificate of analysis NFKK Reference Serum X: a reprint. Scand J Clin Lab Invest 2004;64:321-6.
12. Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP. Immunometric assay interference: incidence and prevention. Clin Chem 2002;48:613-21.
13. Børmer OP, Nustad K. Selection of monoclonal antibodies for use in an immunometric assay for carcinoembryonic antigen. J Immunol Methods 1990;127:171-8.
14. Hammarström S, Shively JE, Paxton RJ, Beatty BG, Larsson Å, Ghosh R, et al. Antigenic sites in carcinoembryonic antigen. Cancer Res 1989;49:4852-8.
15. Børmer O. A direct assay for carcinoembryonic antigen in serum and its diagnostic value in metastatic breast cancer. Clin Biochem 1982;15:128-32.
16. Paus E, Almåsbak H, Børmer OP, Warren DJ. A single-chain Fv based immunofluorometric assay specific for the CEA variant NCA-2. J Immunol Methods 2003.
17. Laurence DJR, Turberville C, Anderson SG, Neville AM. First British standard for carcinoembryonic antigen (CEA). Br J Cancer 1975;32:295-9.
18. Bjorge T, Lie AK, Hovig E, Gislefoss RE, Hansen S, Jellum E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004;91:1829-34.
19. Nustad K, Bast RCJ, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. Tumor Biol 1996;17:196-219.
20. Bjerner J, Norum LF, Nilsson O, Nustad K. MUC1 serum assays in breast cancer: tumor specificities and reference levels. Tumour Biol 2002;23:315-23.
21. Suonpaa MU, Lavi JT, Hemmila IA, Lovgren TN. A new sensitive assay of human alpha-fetoprotein using time-resolved fluorescence and monoclonal antibodies. Clin Chim Acta 1985;145:341-8.
22. Paus E, Nustad K. Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles. Clin Chem 1989;35:2034-8.
23. Paus E, Risberg T. Establishment and evaluation of a radioimmunoassay for neuron- specific enolase. A marker for small cell lung cancer. Tumour Biol 1989;10:23-30.
24. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2007.
25. Lahti A, Hyltoft PP, Boyd JC, Fraser CG, Jorgensen N. Objective criteria for partitioning Gaussian-distributed reference values into subgroups. Clin Chem 2002;48:338-52.
26. Tietz textbook of clinical chemistry, 4th edn. Los Angeles, Calif.: W. B. Saunders. 2005.
27. Stevens DP, Mackay IR. Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet 1973;2:1238-9.
28. Alexander JC, Silverman NA, Chretien PB. Effect of age and cigarette smoking on carcinoembryonic antigen levels. J Am Med Assoc 1976;235:1975-9.
29. Børmer OP. Major disagreement between immunoassays of carcinoembryonic antigen may be caused by nonspecific cross-reacting antigen 2 (NCA-2). Clin Chem 1991;37:1736-9.
30. Bjerner J, Lebedin Y, Bellanger L, Kuroki M, Shively JE, Varaas T, et al. Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 workshop. Tumour Biol 2002;23:249-62.
31. Paus E, Almasbak H, Bormer OP, Warren DJ. A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2. J Immunol Methods 2003;283:125-39.
32. Lopez LA, Del V, Ulla M, Fernandez F, Fernandez LA, Santos I, et al. Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing 1996;25:45-50.
33. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
34. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci 1992;303:157-9.
35. Paus E, Myklebust AT. Expression and interconversion of NSE in patient sera and extracts from small cell lung cancer cells. Tumor Biol 1996.
36. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-7.
37. Jorgensen LG, Lober J, Carlsen NL, Momsen G, Hirsch FR. Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. Clin Chim Acta 1996;249:77-91.
38. Passerini R, Riggio D, Salvatici M, Zorzino L, Radice D, Sandri MT. Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update. Clin Chem Lab Med 2007;45:100-4.
39. Vestergaard EM, Hein HO,Meyer H, Grunnet N, Jorgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61.
40. Horn PS, Feng L, Li Y, Pesce AJ. Effect of outliers and nonhealthy individuals on reference interval estimation. Clin Chem 2001;47:2137-45.